| abstract |
HCV replication inhibitors of the formula (I) (see formula (I)) and the salts and stereoisomers thereof, where each dashed line (represented by -----) represents an optional double bond; X is N, CH and where X carries a double bond, this is C; R1 is -OR7, -NH-SO2R8; R2 is hydrogen, and where X is C or CH, R2 can also be C1-6 alkyl; R3 is hydrogen, C1-6 alkyl, C1-6 alkoxy C1-6 alkyl, C3-7 cycloalkyl; n is 3, 4, 5, or 6; R4 is C1-6 alkyl or C3-7 cycloalkyl; R5 is hydrogen, halo, C1-6 alkyl, hydroxy, C1-6 alkoxy, C1-6 polyhaloalkyl; R6 is hydrogen, C1-6 alkoxy, mono- or C1-6 dialkylamino; or R5 and R6 can form an unsaturated or partially unsaturated ring of 5 or 6 members, optionally comprising one or two selected from O, N and S; R7 is hydrogen; C3-7 cycloalkyl optionally substituted with C1-6 alkyl; or C1-6 alkyl optionally substituted with C3-7 cycloalkyl; R8 is C3-7 cycloaqluyl optionally substituted with C1-6 alkyl; C1-6 alkyl optionally substituted with C3-7 cycloalkyl; or -NR8aR8b; R8a and R8b are C1-6 alkyl, or both can form a saturated 5- or 6-membered heterocyclic ring; pharmaceutical compositions containing the compounds (I) and processes for preparing said compounds (I). |